Abstract:Background: Despite the comparably comprehensive healthcare system in Canada, health inequities are widespread, and this holds true for breast cancer patients in Ontario. It is thus essential to learn if socio-demographic disparities continue after diagnosis of breast cancer, and if these contribute to higher mortality rates in the lower income quintile groups. Methods: We conducted a real-word population-based study using a provincial health administrative dataset from Ontario, Canada. We included patients diagnosed with HER2-negative breast cancer, treated with surgery and adjuvant chemotherapy, between 2009 to 2017. We used log-rank test and Kaplan Meier curves to compare overall survival (OS) between breast cancer populations among income quintile groups, and Cox regression to evaluate risk factors, using hazard ratio (HR) and 95% confidence intervals (CI). Results: We analysed 10,634 women diagnosed with stage I-III breast cancer. At diagnosis, in the Q1 group, there were 248 (15.8%) women with stage I, 997 (63.7%) with stage II, and 320 (20.45%) with stage III. In the Q5 group, there were 568 (22.15%), with stage I, 1,532 (59.75%) with stage II and 464 (18%) with stage III. Comparison between those in the lowest versus highest income quintile groups, and lymph node (LN) status at diagnosis, showed that in Q1, 534 (34%) women had LN 0 and 897 (57.3%) had LN+. In Q5, there were 954 (37.2%) women with LN 0 and 1,379 (53.8%) with LN+. Similarly, comparing tumor size (TS) at diagnosis, we found that in Q1, there were 463 (32.2%) women with TS≤ 2 cm and 974 (67.8%) with TS > 2 cm. In Q5, 915 (39%) women had TS≤ 2 cm and 1,426 (61%) had TS > 2 cm. In the Q1 group, there were 325 (20.7%) patients who received non- anthracycline and 1,240 (79.3%) treated with anthracycline-taxane chemotherapy. In Q5, there were 673 (26.2%) women treated with non-anthracycline and 1,891 (73.8%) who received anthracycline-taxane chemotherapy. The OS analysis based on the household income group compared to Q5 showed a substantial difference in the Q1 (HR 1.52, 1.2–1.9, p = 0.0002) and Q2 (HR 1.34, 1.1–1.7, p = 0.006) groups. In Cox regression models, Q5 group and endocrine receptor (ER) positive were significantly associated with reduced mortality risk. There was a significant correlation between increased risk of death and the following: receipt of non- anthracycline chemotherapy, TS > 2 cm, LN+ and grade 3 histology. Conclusion: Our study found an uneven distribution of breast cancer patients between the lowest and highest income quintile groups. Women with HER2-negative breast cancer who were part of the lower income quintile groups, thereby likely with a socioeconomic disadvantage, had the lowest OS. At diagnosis, these women were more likely to have more advanced breast cancer staging, including larger tumors, LN+, and receive anthracycline-based chemotherapy as compared to those with higher household income. Further research is warranted to identify the key social determinants that are systematically associated with disparities in equitable access to care. Citation Format: Danilo Giffoni M. M. Mata, Rossanna C. Pezo, Kelvin K.W. Chan, Ines Menjak, Andrea Eisen, Maureen Trudeau. Reduced survival outcomes in lower income quintile groups for women with breast cancer treated with chemotherapy in Ontario, Canada [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl) nr B006.

Breast cancer mortality among ultra-orthodox and non-ultra-orthodox Israeli women: A retrospective cohort study

Cardiovascular disease risk factors and health behaviors of ultra-Orthodox Jewish women in Israel: a comparison study

Health Disparities Among Ultra-Orthodox and Non-Ultra-Orthodox Residents in Neighboring Cities in Israel: A Cross-Sectional Study

Breast cancer insights from Northern Israel: a comprehensive analysis of survival rates among Jewish and Arab women

Ethnic disparities in the incidence of gynecologic malignancies among Israeli Women of Arab and Jewish Ethnicity: a 10-year study (2010-2019)

Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates

Understanding Social, Cultural, and Religious Factors Influencing Medical Decision-Making on BRCA1/2 Genetic Testing in the Orthodox Jewish Community

Subfertility, use of fertility treatments and BRCA mutation status and the risk of ovarian cancer

Motives for Vaccination Against COVID-19 Among the Ultra-orthodox Jewish Community in Israel

Jewish ethnicity and prostate cancer mortality in two large US cohorts

Cesarean Sections and Family Planning Among Ultra-Orthodox Israeli Jews

Factors associated with major adverse cardiovascular events among Arabs and Jews in Israel: a population-based cohort study

Knowledge of risk factors and prevention of osteoporosis: the Israeli women's health at midlife study

Associations of adolescent obesity with hypertension, diabetes mellitus and polycystic ovaries in Arabs and Jews in Israel—a nationwide study

Subjective Nearness-to-Death and COVID-19 Worries Among Ultra-Orthodox Jews in Israel: The Moderating Role of Israeli Identity and Sense of Community

Religious Differences in Physical and Mental Health among Israeli Jews: Findings from the Global Flourishing Study

Pilot study of a decision aid on BRCA1/2 genetic testing among Orthodox Jewish women

Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer in the United States, Europe, and Israel

Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers: a single institution experience

Perceptions among diabetic patients in the ultra-orthodox Jewish community regarding medication adherence: a qualitative study

Abstract B006: Reduced survival outcomes in lower income quintile groups for women with breast cancer treated with chemotherapy in Ontario, Canada